News
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...
1h
Investor's Business Daily on MSNNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic
Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...
Bloomberg on MSN8h
Novo CFO: US Wegovy, Ozempic Prices to Keep Falling
The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...
Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...
GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results